SCHEMBL29664453

SCHEMBL29664453

CC(C)(C)OC(=O)N1CCN(c2ccccc2N)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMARCA2 P51531 1/20 0.60
SMARCA4 P51532 1/20 0.60
PBRM1 Q86U86 1/20 0.60
ADRA2C P18825 1/20 0.53
GPR119 Q8TDV5 2/20 0.52
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
CKS1B P61024 2/20 0.51
SKP1 P63208 2/20 0.51
SKP2 Q13309 2/20 0.51
NAMPT P43490 1/20 0.50
PTPN11 Q06124 1/20 0.50
MAP4K4 O95819 1/20 0.49
GAA P10253 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
KIT P10721 1/20 0.48
CHRM2 P08172 1/20 0.48
CHRM4 P08173 1/20 0.48
CHRM1 P11229 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2843440 1.00 SMARCA2 (0.60) SMARCA2SMARCA4PBRM1ADRA2CGPR119
SCHEMBL29664457 1.00 SMARCA2 (0.60) SMARCA2SMARCA4PBRM1ADRA2CGPR119
SCHEMBL1249642 0.89 SMARCA2 (0.55) SMARCA2SMARCA4PBRM1GPR119ALDH1A1
SCHEMBL31152780 0.89 SMARCA2 (0.55) SMARCA2SMARCA4PBRM1GPR119ALDH1A1
SCHEMBL4678427 0.87 SMARCA2 (0.57) SMARCA2SMARCA4PBRM1GPR119ALDH1A1
SCHEMBL31640089 0.86 SMARCA2 (0.53) SMARCA2SMARCA4PBRM1GPR119ALDH1A1
SCHEMBL4133762 0.85 GPR119 (0.52) SMARCA2SMARCA4PBRM1GPR119ALDH1A1
SCHEMBL23368541 0.85 ADRA2C (0.56) ADRA2CALDH1A1MAPTGAASMN1; SMN2
SCHEMBL17276765 0.85 CKS1B (0.55) SMARCA2SMARCA4PBRM1GPR119ALDH1A1
SCHEMBL14206383 0.84 CYP11B2 (0.55) SMARCA2SMARCA4PBRM1ADRA2CGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129074-A1 CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2025-04-24 US disclosed
EP-4438603-A1 CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2024-10-02 EP disclosed
CN-118234726-A Chimeric compound for androgen receptor protein targeted degradation, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2024-06-21 CN disclosed
EP-3102193-B1 ANTIBACTERIAL AGENTS: N(ALPHA)-AROYL-N-ARYL-PHENYLALANINAMIDES UNIV RUTGERS (US) 2023-01-11 EP disclosed
CN-110157251-B Curing agent composition and coating composition comprising same KCC公司 2022-04-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129074-A1 CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF AR, NR5A1, CYP17A1 SMARCA2 4116/4885SMARCA4 4073/4885PBRM1 2179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.